SB 706504 

SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD)^[1].

SB 706504 (3 μM, 6 h)可显着降低 IL-1β、IL-6、GM-CSF、TNFα 和 IL-8 mRNA 水平，在 LPS 刺激的 单核细胞来源的巨噬细胞 （MDM）中^[1]。
SB 706504(3 μM, 6 h)可显着降低 COPD 患者肺泡巨噬细胞（AM）中 LPS 诱导的 TNFα 水平，抑制率为 67.4%^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

492.46

C₂₄H₁₉F₃N₈O

911110-38-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lauren M. Kent, et al. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504).